Afimetoran

Generic Name: Afimetoran

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₂N_₆O

CAS Number: 2171019-55-7

Unique Ingredient Identifier: LXP7MZL0VF

Background: Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Afimetoran
Other: Placebo

First Posted Date: 2021-05-20

Last Posted Date: 2025-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 268

Registration Number: NCT04895696

Locations: 🇺🇸
Overlake Arthritis and Osteoporosis Center, Bellevue, Washington, United States
🇦🇺
Local Institution - 0072, Westmead, New South Wales, Australia
🇨🇴
Centro de Reumatologia y Ortopedia, Barranquilla, Colombia

and more 171 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy